Weekly Round Up

Research Deep DiveSurveysExpert CallLong Form ArticleWeekly Round Up
Weekly Round UpWeekly Round Up
The Healthcare M&A Playbook Is Changing

The Healthcare M&A Playbook Is Changing

We’re diving into the factors when evaluating an acquisition target, pressure on drug pricing reforms big European companies, Thoreau’s $12B RCM bet, and APAC healthcare current status.

Weekly Round UpWeekly Round Up
Healthcare's 3 Biggest Bets: M&A, AI Agents, and GLP-1s

Healthcare's 3 Biggest Bets: M&A, AI Agents, and GLP-1s

We explore 2026 healthcare M&A sentiment, examine how the healthcare industry is rapidly adopting multi-agent AI systems, and analyze why the oral GLP-1 market is projected to reach $137.4 billion by 2035.

Weekly Round UpWeekly Round Up
Pharma’s China Dependency Is Becoming a Security Risk

Pharma’s China Dependency Is Becoming a Security Risk

Diving into the APAC Healthcare Bottleneck, GSK is acquiring Nuvalent for $10.6B in cash, marking the largest acquisition in the company’s history.

Weekly Round UpWeekly Round Up
Healthcare’s Next Wave Is Getting More Personalized

Healthcare’s Next Wave Is Getting More Personalized

Diving into the precision medicine market size, Medtech VC funding overview, Oncology dominators competitive landscape, and the increasing number of health and fitness apps usage

Weekly Round UpWeekly Round Up
What’s Blocking Healthcare M&A Right Now

What’s Blocking Healthcare M&A Right Now

Healthcare M&A hurdles, regional satisfaction gaps, and wearable tech’s clinical shift.

Weekly Round UpWeekly Round Up
Healthcare’s Next Margin Playbook Starts With AI

Healthcare’s Next Margin Playbook Starts With AI

Diving into the main cost drivers of Hospitals and the Healthcare Industry to understand what is the next margin playbook in the sector.

Weekly Round UpWeekly Round Up
The $10.7B Pharma Deal Reshaping European Healthcare

The $10.7B Pharma Deal Reshaping European Healthcare

We’re unpacking the forces slowing healthcare M&A acceleration in 2026, CVC’s €10.7B bet on European pharma, the rise of oral GLP-1 therapies as scalable healthcare infrastructure, and how Europe and Asia are emerging as a new global healthcare capital axis.

Weekly Round UpWeekly Round Up
Biopharma’s Great Reset Meets a Rural Staffing Squeeze

Biopharma’s Great Reset Meets a Rural Staffing Squeeze

We’re diving into the Biopharma reset, the share of new medicine reimbursement by public insurance, CMS scrutiny expansion, and rural healthcare PA cliff.

Weekly Round UpWeekly Round Up
Biotech Is Back. And Healthcare PE Knows It

Biotech Is Back. And Healthcare PE Knows It

From biotech’s M&A momentum to home health consolidation and rising affordability risks, here’s what’s shaping healthcare strategy in 2026.

Weekly Round UpWeekly Round Up
Healthcare’s $1.5T Shift Out of the Hospital

Healthcare’s $1.5T Shift Out of the Hospital

We’re unpacking the rise of home-based healthcare, how mHealth is evolving from wellness apps into core healthcare infrastructure, the growing reimbursement risks tied to workforce compliance, and why healthcare inflation is becoming a permanent global operating challenge.

Weekly Round UpWeekly Round Up
Europe Is Quietly Winning the Clinical Trial Race

Europe Is Quietly Winning the Clinical Trial Race

healthcare’s renewed focus on outbreak containment, private equity’s continued bet on healthcare staffing infrastructure, Europe’s growing advantage in clinical trial density, and the operational race to build faster, more resilient healthcare systems worldwide.

Weekly Round UpWeekly Round Up
CMS Is Tightening RPM Audits — Investors Should Pay Attention

CMS Is Tightening RPM Audits — Investors Should Pay Attention

We unpack the explosive growth of Remote Patient Monitoring (RPM) and the massive opportunity emerging for healthcare investors.